ASX: RMD | NYSE: RMD | Market Cap: ~$50 billion AUD | Sector: Healthcare/Medical Devices

---

Company Overview

ResMed Inc. is a global leader in digital health and cloud-connected medical devices for treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company develops, manufactures, and distributes innovative solutions that improve quality of life, reduce healthcare costs, and help people breathe better and sleep better.

Key Facts

• Founded: 1989 by Dr. Peter Farrell
• Headquarters: San Diego, California, USA
• ASX Listing: 1995 (Primary listing)
• NYSE Listing: 1995 (Secondary listing via CDIs)
• CEO: Mick Farrell (son of founder)
• Employees: 10,000+ globally
• Operations: 140+ countries
• Market Position: #1 global sleep apnea device manufacturer (~50% market share)
• Patients: 180+ million people in 140+ countries use ResMed cloud-connected devices

---

Product Portfolio

1. Sleep Apnea Devices

What is Sleep Apnea?
A serious sleep disorder where breathing repeatedly stops and starts during sleep. Obstructive Sleep Apnea (OSA) occurs when throat muscles relax and block the airway. Untreated sleep apnea increases risk of heart disease, stroke, diabetes, and accidents.

CPAP/BiPAP Devices (Continuous/Bilevel Positive Airway Pressure)

AirSense™ Series

• AirSense 11 – Latest generation, launched 2021
• AirSense 10 – Most popular model globally
• AirSense 10 AutoSet – Auto-adjusting pressure
• AirSense 10 Elite – Fixed pressure
• AirSense 10 AutoSet for Her – Algorithm optimized for women

Key Features:

• AutoRamp™ – Gradual pressure increase for comfort
• Climate Control – Heated humidifier with temperature control
• Expiratory Pressure Relief (EPR) – Easier exhalation
• Quiet operation – 26 decibels (whisper-quiet)
• Cloud connectivity – Automatic data upload to myAir™ app
• Integrated wireless – 4G/5G cellular connectivity

AirCurve™ Series (BiPAP)

• AirCurve 10 VAuto – Auto-adjusting bilevel therapy
• AirCurve 10 S – Fixed bilevel pressure
• AirCurve 10 ST – With backup respiratory rate
• AirCurve 10 ASV – Adaptive servo-ventilation for central sleep apnea

Indications:

• Obstructive Sleep Apnea (OSA)
• Central Sleep Apnea (CSA)
• Complex Sleep Apnea
• Cheyne-Stokes respiration
• COPD with sleep-disordered breathing

Revenue Contribution: ~60% of total ResMed revenue

---

Masks and Accessories

Mask Types

Nasal Masks

• AirFit N30i – Top-of-head tube connection, minimal contact
• AirFit N20 – Most popular nasal mask
• AirFit N30 – Compact, lightweight design

Nasal Pillow Masks

• AirFit P10 – Ultra-lightweight, quiet
• AirFit P30i – Top-of-head design
• Swift FX – Minimal design for active sleepers

Full Face Masks

• AirFit F30i – Under-nose full face, top connection
• AirFit F20 – InfinitySeal™ cushion technology
• AirTouch F20 – Memory foam cushion
• Quattro Air – For mouth breathers

For Her Series

• AirFit N20 for Her – Smaller sizing, softer headgear
• AirFit P10 for Her – Designed for female facial features
• AirTouch F20 for Her – Optimized fit

Key Technologies:

• QuietAir™ vent – Reduces noise to 21 decibels
• InfinitySeal™ – Adaptive cushion for various sleeping positions
• Magnetic clips – Easy assembly and disassembly
• Quick-release elbow – Easy disconnection at night

Accessories

• Replacement cushions and headgear
• Tubing (standard and heated ClimateLineAir™)
• Filters (disposable and reusable)
• Water chambers for humidifiers
• Travel bags and portable batteries

Revenue Contribution: ~25% of total ResMed revenue (high-margin recurring revenue)

---

2. Respiratory Care Devices

Non-Invasive Ventilation (NIV)

Lumis™ Series

• Lumis 150 VPAP ST – Volume-targeted ventilation
• Lumis 100 VPAP S – Spontaneous mode ventilation
• Stellar™ Series – Life-support ventilators for hospital/home use

Indications:

• Chronic Obstructive Pulmonary Disease (COPD)
• Neuromuscular disease (ALS, muscular dystrophy)
• Obesity hypoventilation syndrome (OHS)
• Restrictive lung disease
• Post-polio syndrome

High-Flow Therapy

Astral™ Series

• Life-support ventilator for invasive and non-invasive ventilation
• Hospital and home use
• Pediatric and adult applications

Revenue Contribution: ~10% of total ResMed revenue

---

3. Software as a Service (SaaS) Solutions

Patient Engagement Platforms

myAir™

• Mobile app for CPAP users
• Daily sleep score and therapy data
• Personalized coaching and tips
• Mask fit guidance
• Troubleshooting support
• Engagement: 7+ million active users

AirView™

• Cloud-based patient management platform for healthcare providers
• Remote monitoring of therapy compliance
• Automated alerts for intervention
• Population health analytics
• Users: 20+ million patients monitored

Out-of-Hospital Software

Brightree® (Acquired 2016 for $800M)

• Cloud-based business management software for home medical equipment (HME) providers
• Revenue cycle management
• Inventory and warehouse management
• Patient intake and documentation
• Billing and claims processing
• Customers: 2,500+ HME providers

MatrixCare® (Acquired 2018 for $750M)

• Software for senior living and post-acute care facilities
• Electronic health records (EHR)
• Care coordination and clinical documentation
• Medication management
• Billing and compliance
• Customers: 13,000+ senior living facilities

MEDIFOX DAN® (Acquired 2021 for $1B)

• Leading out-of-hospital software provider in Germany
• Home care, hospice, and nursing home software
• Care planning and documentation
• Billing and regulatory compliance
• Customers: 17,000+ care providers in Germany

Revenue Contribution: ~5% of total ResMed revenue (growing rapidly, high margins)

---

Market Opportunity

Sleep Apnea Market

Global Prevalence

• 936 million adults worldwide have mild to severe OSA (Lancet 2019)
• 425 million adults have moderate to severe OSA requiring treatment
• 80-90% undiagnosed – Massive awareness gap
• Prevalence increasing – Obesity epidemic driving growth

Market Penetration

• USA: ~20% diagnosed and treated
• Europe: ~15% diagnosed and treated
• Asia: ~5% diagnosed and treated
• Global average: ~10% penetration
• Opportunity: 380+ million untreated patients

Risk Factors

• Obesity: 70% of OSA patients are obese
• Age: Prevalence increases with age
• Gender: 2-3x more common in men (but underdiagnosed in women)
• Neck circumference: Larger neck = higher risk
• Family history: Genetic component

Health Consequences of Untreated Sleep Apnea

• Cardiovascular: 2-3x increased risk of heart attack, stroke, atrial fibrillation
• Metabolic: Increased risk of type 2 diabetes, metabolic syndrome
• Cognitive: Memory problems, difficulty concentrating, dementia risk
• Mental health: Depression, anxiety
• Accidents: 5x increased risk of motor vehicle accidents
• Mortality: 3x increased all-cause mortality if severe and untreated

COPD and Respiratory Market

Global Prevalence

• 384 million people worldwide have COPD (WHO)
• 3.2 million deaths annually from COPD
• 4th leading cause of death globally
• Prevalence increasing – Aging populations, air pollution

Market Opportunity

• Non-invasive ventilation for COPD exacerbations
• Home ventilation for chronic respiratory failure
• Hospital-to-home transitions
• Reducing hospital readmissions

Out-of-Hospital Care Market

Secular Trends

• Aging populations: 65+ age group fastest growing demographic
• Healthcare cost pressures: Shift from hospital to home care
• Chronic disease management: Growing need for remote monitoring
• Value-based care: Payment models rewarding outcomes, not volume
• Technology enablement: Cloud connectivity, telehealth, AI

Market Size

• Home medical equipment (HME): $30B+ annual market
• Senior living facilities: $400B+ annual market
• Home healthcare: $300B+ annual market
• Software opportunity: Digitizing fragmented, paper-based industry

---

Geographic Revenue Mix

Revenue by Region (FY2024 estimates)

Region	Revenue %	Key Markets	Growth Rate
Americas	60%	USA, Canada, Latin America	10-12%
Europe	25%	Germany, France, UK, Nordics	8-10%
Asia Pacific	15%	Australia, Japan, China, India	15-20%

United States (50% of revenue)

• Largest and most mature market
• Strong reimbursement from Medicare and private insurance
• High awareness and diagnosis rates
• Competitive market with Philips Respironics

Europe (25% of revenue)

• Fragmented market with country-specific reimbursement
• Germany largest European market
• Growing home care adoption
• MEDIFOX DAN acquisition strengthens position

Asia Pacific (15% of revenue)

• Fastest growing region (15-20% annually)
• Low current penetration, high growth potential
• Rising obesity rates driving sleep apnea prevalence
• Expanding middle class and healthcare access
• China, India, Southeast Asia key growth markets

---

Competitive Landscape

Sleep Apnea Market

1. ResMed

• Market share: ~50% globally
• Strengths: Technology leadership, cloud connectivity, mask innovation, SaaS ecosystem
• Position: Market leader

2. Philips Respironics (Philips)

• Market share: ~35% globally (declining due to recall)
• Strengths: Brand recognition, hospital relationships, DreamStation platform
• Challenges: Major product recall (2021-present) – foam degradation issue affecting 15+ million devices
• Impact: ResMed gained significant market share during recall

3. Fisher & Paykel Healthcare

• Market share: ~10% globally
• Strengths: Mask innovation (Evora, Simplus), humidification technology
• Focus: Masks and hospital respiratory care

4. Lowenstein Medical (Germany)

• Market share: ~3% globally
• Strengths: Strong European presence, hospital ventilation

5. BMC Medical (China)

• Market share: ~2% globally
• Strengths: Low-cost devices for emerging markets

ResMed’s Competitive Advantages

✅ Technology leadership: Cloud-connected devices, AI algorithms, data analytics
✅ Mask portfolio: Broadest range, highest comfort and seal performance
✅ Digital ecosystem: myAir, AirView, remote monitoring
✅ Manufacturing scale: Vertically integrated, cost advantages
✅ Clinical evidence: Extensive outcome studies, peer-reviewed research
✅ Brand loyalty: High patient and provider satisfaction
✅ SaaS moat: Software platforms create switching costs
✅ Philips recall windfall: Gained 5-10% market share permanently

---

Business Model

Revenue Streams

1. Device Sales (60% of revenue)

• CPAP/BiPAP machines: $500-$3,000 per device
• Ventilators: $5,000-$25,000 per device
• Gross margin: 55-60%
• Replacement cycle: 5-7 years (insurance coverage)

2. Masks & Accessories (30% of revenue)

• Masks: $50-$150 per mask
• Replacement: Every 3-6 months (insurance coverage)
• Accessories: Tubing, filters, water chambers
• Gross margin: 65-70% (highest margin segment)
• Recurring revenue: Predictable, annuity-like

3. Software & Services (10% of revenue)

• SaaS subscriptions: $50-$500 per user/month
• Brightree, MatrixCare, MEDIFOX DAN
• Gross margin: 70-75%
• Recurring revenue: High retention, low churn
• Growth: 15-20% annually

Reimbursement Model

United States

• Medicare: Covers CPAP therapy after sleep study and compliance demonstration
• Private insurance: Most plans cover with prior authorization
• Durable Medical Equipment (DME) model: 13-month rental-to-own
• Compliance requirement: 4+ hours/night for 70% of nights in first 90 days
• Remote monitoring: Enables compliance verification without clinic visits

Europe

• National health systems: Government reimbursement (UK NHS, German GKV)
• Rental models: Common in some countries
• Purchase models: Patient buys device in other countries
• Variation: Reimbursement rates and policies vary by country

Asia Pacific

• Mixed model: Government, private insurance, out-of-pocket
• Growing coverage: Expanding reimbursement in China, Japan
• Affordability programs: Lower-priced devices for emerging markets

---

Research & Development

R&D Investment

• Annual R&D spend: ~$300 million USD (~7% of revenue)
• R&D centers: San Diego (USA), Sydney (Australia), Singapore
• Focus areas: AI/machine learning, cloud connectivity, mask comfort, miniaturization
• Patents: 5,000+ patents and applications globally

Innovation Pipeline

Near-Term (2026-2027)

• AirSense 12: Next-generation CPAP with enhanced AI
• New mask platforms: Improved comfort and seal
• AI sleep coaching: Personalized therapy optimization
• Expanded myAir features: Sleep quality insights, health integrations

Medium-Term (2028-2030)

• Wearable sleep apnea diagnostics: Home sleep testing devices
• Oral appliance integration: Connected mandibular advancement devices
• Predictive analytics: AI predicting therapy adherence and outcomes
• Telehealth platform: Virtual sleep medicine consultations

Long-Term (2031+)

• Implantable devices: Hypoglossal nerve stimulation (competing with Inspire Medical)
• Pharmacological therapies: Drug development for sleep apnea
• Biological interventions: Gene therapy, tissue engineering

Key Technology Differentiators

AutoSet™ Algorithm

• Automatically adjusts pressure breath-by-breath
• Responds to apneas, hypopneas, flow limitations
• Delivers lowest effective pressure for comfort

Climate Control

• Heated humidifier with adaptive temperature
• Heated tubing prevents condensation (“rainout”)
• Maintains optimal humidity throughout night

Cloud Connectivity

• Automatic wireless data upload (4G/5G cellular)
• Real-time therapy monitoring
• Remote troubleshooting and adjustments
• Population health analytics

AI and Machine Learning

• Predictive algorithms for therapy adherence
• Personalized coaching recommendations
• Automated intervention triggers
• Sleep quality scoring

---

Financial Performance

Revenue Trends (FY2024 estimates)

• Total revenue: ~$4.5 billion USD
• Revenue growth: 10-12% annually
• Devices: $2.7B (60%)
• Masks & accessories: $1.35B (30%)
• Software & services: $450M (10%)

Profitability Metrics

• Gross margin: 58-62%
• Operating margin: 28-32%
• Net profit margin: 20-24%
• Return on equity (ROE): 25-30%
• EBITDA margin: 32-36%

Dividend History

• Dividend policy: Quarterly dividends
• Payout ratio: 40-50% of net profit
• Franking: Unfranked (US-based company)
• Yield: Typically 1.5-2.0%
• Track record: 15+ years of consecutive dividend increases
• Growth rate: 10-15% annual dividend growth

Balance Sheet

• Cash position: $500M+ USD
• Debt: $1.5B USD (manageable, low leverage)
• Net debt/EBITDA: ~1.0x (conservative)
• Working capital: Efficient inventory management
• Capex: ~3% of revenue (manufacturing, IT infrastructure)
• Free cash flow conversion: 95-100% of net profit

Capital Allocation

• R&D investment: 7% of revenue
• Dividends: 40-50% payout
• Share buybacks: Opportunistic repurchases
• M&A: Strategic acquisitions (Brightree, MatrixCare, MEDIFOX DAN)
• Organic growth: Manufacturing capacity expansion

---

Investment Thesis

Bull Case 🐂

Structural Growth Drivers

• Massive undiagnosed population: 80-90% of sleep apnea patients undiagnosed
• Obesity epidemic: 70% of OSA patients are obese; obesity rates rising globally
• Aging demographics: Sleep apnea prevalence increases with age
• Awareness campaigns: Reducing stigma, increasing diagnosis
• Comorbidity recognition: Links to cardiovascular disease, diabetes driving screening

Philips Recall Windfall

• Market share gains: ResMed captured 5-10% additional market share
• Permanent shift: Patients and providers switching to ResMed
• Brand damage: Philips reputation harmed, slow recovery
• Supply constraints easing: ResMed ramped production to meet demand

Recurring Revenue Model

• Mask replacements: Every 3-6 months, high-margin recurring revenue
• Device upgrades: 5-7 year replacement cycle
• Growing installed base: 15+ million active patients
• SaaS revenue: Software subscriptions growing 15-20% annually
• Lifetime value: Each patient worth $5,000-$10,000 over lifetime

Digital Health Ecosystem

• Cloud connectivity: 180M+ cloud-connected devices
• myAir engagement: 7M+ active users, high satisfaction
• Remote monitoring: Reduces healthcare costs, improves outcomes
• Data moat: Billions of nights of sleep data for AI/ML
• Platform stickiness: Ecosystem creates switching costs

Software Growth Opportunity

• Brightree, MatrixCare, MEDIFOX DAN: $1B+ annual revenue potential
• Fragmented market: Digitizing paper-based workflows
• High margins: 70-75% gross margins on software
• Recurring revenue: SaaS model with low churn
• Cross-selling: Device + software bundling opportunities

Emerging Market Expansion

• Asia Pacific growth: 15-20% annually
• China opportunity: Low penetration, expanding reimbursement
• India potential: 1.4B population, rising obesity
• Middle East: High OSA prevalence, government programs

Defensive Characteristics

• Essential medical device: Not discretionary spending
• Recession-resistant: Healthcare spending stable
• Reimbursement coverage: Medicare, private insurance
• High switching costs: Patients and providers loyal

Bear Case 🐻

Risks and Challenges

Philips Recovery

• Philips resolving recall, returning to market
• Competitive intensity increasing
• Price competition to regain market share
• ResMed’s windfall gains may moderate

Reimbursement Pressure

• Medicare reimbursement rate cuts
• Shift to competitive bidding (lower prices)
• Insurance prior authorization barriers
• Value-based care models reducing device payments

Market Saturation

• US market maturing (20% penetration)
• Slower growth in developed markets
• Diagnosis rates plateauing
• Patient adherence challenges (30-40% discontinue therapy)

Alternative Therapies

• Inspire Medical: Hypoglossal nerve stimulation (implantable device)
• Oral appliances: Mandibular advancement devices
• Positional therapy: Devices preventing supine sleep
• Weight loss drugs: GLP-1 agonists (Ozempic, Wegovy) reducing obesity
• Surgical options: UPPP, maxillomandibular advancement

Emerging Market Execution

• Slower-than-expected reimbursement expansion
• Affordability barriers in developing countries
• Local competition (Chinese manufacturers)
• Regulatory approval delays

Currency Exposure

• ~60% revenue in USD, costs in AUD
• AUD weakness benefits, but AUD strength hurts
• Euro and other currency fluctuations
• Hedging strategies have costs

Valuation

• Trades at premium multiples (28-32x P/E)
• High expectations priced in
• Limited margin of safety
• Sensitive to growth disappointments

Supply Chain Risks

• Component shortages (semiconductors)
• Manufacturing disruptions (COVID-19 lockdowns)
• Logistics challenges
• Inflation pressuring input costs

---

Valuation Metrics

Current Trading Multiples (indicative)

• P/E Ratio: 28-32x
• Forward P/E: 25-28x
• Price-to-Sales: 6-8x
• Price-to-Book: 7-9x
• EV/EBITDA: 20-24x
• Dividend Yield: 1.5-2.0%

Comparison to Peers

Company	P/E	Div Yield	Market Cap	Focus
ResMed	30x	1.8%	$50B AUD	Sleep/respiratory
Cochlear	34x	1.7%	$20B AUD	Hearing implants
CSL	30x	1.2%	$140B AUD	Biotechnology
Fisher & Paykel	35x	1.5%	$20B NZD	Respiratory/humidification
Philips	15x	3.0%	$25B EUR	Healthcare (recall impact)

Observation: ResMed trades at premium to diversified healthcare companies, in line with high-growth medical device peers

---

Key Catalysts to Monitor

Near-Term (2026)

• Quarterly earnings: Revenue growth, margin expansion, guidance
• Philips recall resolution: Competitive dynamics post-recall
• Mask launches: New mask platforms driving growth
• Software revenue: SaaS growth trajectory
• China expansion: Reimbursement and market penetration

Medium-Term (2027-2028)

• AirSense 12 launch: Next-generation CPAP platform
• Emerging market growth: Asia Pacific revenue acceleration
• Software M&A: Additional acquisitions in out-of-hospital care
• AI integration: Machine learning features driving differentiation
• Market share trends: Sustaining gains from Philips recall

Long-Term (2029+)

• Implantable devices: Entry into hypoglossal nerve stimulation market
• Global penetration: Progress toward 20-30% market penetration
• Digital health ecosystem: Platform expansion beyond sleep apnea
• Pharmacological therapies: Drug development partnerships

---

How to Invest in ResMed

Direct Stock Purchase

• ASX: RMD – Australian Securities Exchange (primary listing)
• NYSE: RMD – New York Stock Exchange (CDIs – CHESS Depositary Interests)
• Available through Australian and US brokers
• Unfranked dividends (US-based company)
• Highly liquid stock – easy to buy/sell

ETF Exposure

• VanEck Australian Healthcare ETF (HLTH) – ~15% RMD weighting
• iShares S&P/ASX 200 ETF (IOZ) – ~2% RMD weighting
• Vanguard Australian Shares Index ETF (VAS) – ~2% RMD weighting
• Global healthcare ETFs – Some international exposure

Superannuation

• Most Australian super funds hold ResMed
• Check your fund’s portfolio allocation
• Consider increasing healthcare sector exposure

---

Analyst Consensus (Indicative)

Ratings Distribution

• Buy: 65% of analysts
• Hold: 30% of analysts
• Sell: 5% of analysts

Price Target Range

• Bull case: $40-45 AUD
• Base case: $35-38 AUD
• Bear case: $28-32 AUD

Note: Analyst opinions vary based on Philips recovery timeline and emerging market growth assumptions

---

Tax Considerations (Australian Investors)

Dividends

• Franking credits: Unfranked (0%) – US-based company
• Withholding tax: 15% US withholding tax on dividends (reduced by tax treaty)
• Foreign income tax offset: Can claim credit for US tax paid
• Dividend reinvestment plan (DRP): Not currently offered

Capital Gains

• CGT discount: 50% discount for holdings over 12 months
• Currency gains/losses: USD/AUD exchange rate impacts returns
• Record keeping: Track cost base in AUD for tax purposes

Currency Considerations

• ResMed reports in USD
• ASX listing trades in AUD (converted from USD)
• Currency fluctuations impact AUD returns
• AUD weakness = higher AUD share price (and vice versa)

---

ESG Considerations

Environmental

• Manufacturing energy efficiency programs
• Renewable energy usage in facilities
• Waste reduction and recycling initiatives
• Sustainable packaging materials
• Carbon footprint reduction targets

Social

• Patient access programs: Affordable devices for underserved populations
• Sleep health advocacy: Awareness campaigns, education
• Clinical research: Funding sleep apnea studies
• Employee wellbeing: Health and safety programs
• Diversity and inclusion: Workforce representation goals
• Community engagement: Charitable donations, volunteering

Governance

• Independent board with medical device expertise
• Executive compensation tied to long-term performance
• Transparent financial reporting
• Strong regulatory compliance culture
• Ethical marketing and sales practices
• Data privacy and cybersecurity measures

ESG Ratings: Generally strong scores from major rating agencies (MSCI, Sustainalytics)

---

Comparison: ResMed vs Other ASX Healthcare Stocks

Stock	Focus	Market Cap	P/E	Div Yield	Growth Rate
RMD	Sleep/respiratory	$50B	30x	1.8%	10-12%
CSL	Plasma, vaccines	$140B	30x	1.2%	7-9%
COH	Hearing implants	$20B	34x	1.7%	8-10%
SHL	Pathology	$10B	18x	3.5%	3-5%
PME	Medical imaging	$15B	120x	0.5%	20-25%

---

Patient Journey: CPAP Therapy

Step 1: Symptoms Recognition

• Loud snoring
• Witnessed breathing pauses during sleep
• Gasping or choking at night
• Excessive daytime sleepiness
• Morning headaches
• Difficulty concentrating
• Irritability or mood changes

Step 2: Diagnosis

• Primary care visit: Discuss symptoms with doctor
• Sleep study referral: Polysomnography (PSG) or home sleep test (HST)
• Sleep study: Monitors breathing, oxygen levels, brain activity, heart rate
• Diagnosis: Apnea-Hypopnea Index (AHI) determines severity
  • Mild: 5-15 events/hour
  • Moderate: 15-30 events/hour
  • Severe: 30+ events/hour

Step 3: CPAP Prescription

• Sleep physician prescribes CPAP therapy
• Pressure settings determined (fixed or auto-adjusting)
• Referral to durable medical equipment (DME) provider

Step 4: Device Setup

• Mask fitting: Try different mask styles (nasal, nasal pillow, full face)
• Device training: Learn to use and maintain CPAP
• Humidifier setup: Adjust temperature and humidity settings
• Ramp feature: Gradual pressure increase for comfort
• myAir app: Download app for daily feedback

Step 5: Adaptation Period (First 30 Days)

• Initial discomfort: Mask pressure, claustrophobia common
• Gradual use: Start with naps, increase to full nights
• Troubleshooting: Mask leaks, dry mouth, nasal congestion
• Follow-up: DME provider or sleep clinic check-ins
• Compliance monitoring: Remote data review

Step 6: Long-Term Therapy

• Daily use: 4+ hours/night for insurance compliance
• Maintenance: Daily cleaning, weekly deep cleaning
• Supplies replacement: Masks every 3-6 months, filters monthly
• Annual check-ups: Sleep physician reviews therapy data
• Device upgrades: New CPAP every 5-7 years (insurance coverage)

Outcomes

• Symptom improvement: Reduced snoring, better sleep quality, increased energy
• Health benefits: Lower blood pressure, reduced cardiovascular risk, improved glucose control
• Quality of life: Better mood, concentration, productivity
• Adherence: 60-70% of patients continue therapy long-term

---

Related Terms

• Sleep apnea – Breathing disorder during sleep
• Obstructive Sleep Apnea (OSA) – Airway blockage during sleep
• Central Sleep Apnea (CSA) – Brain signal failure to breathe
• CPAP – Continuous Positive Airway Pressure
• BiPAP – Bilevel Positive Airway Pressure
• Apnea-Hypopnea Index (AHI) – Sleep apnea severity measure
• COPD – Chronic Obstructive Pulmonary Disease
• Polysomnography (PSG) – Overnight sleep study
• Home Sleep Test (HST) – Portable sleep monitoring device
• Durable Medical Equipment (DME) – Long-lasting medical devices

---

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. ResMed stock carries risks including competitive pressures, reimbursement changes, currency fluctuations, and alternative therapy adoption. DYOR before making investment decisions. Past performance is not indicative of future results. Consult with healthcare professionals regarding sleep apnea diagnosis and treatment.

---

Official Website: www.resmed.com

Investor Relations: investor.resmed.com

ASX Announcements: www.asx.com.au (Code: RMD)

NYSE Listing: www.nyse.com (Code: RMD)

Related Topics: ResMed, ASX:RMD, NYSE:RMD, Healthcare Stocks, Medical Devices, Sleep Apnea, CPAP Therapy, Respiratory Devices, Australian Stocks, Growth Stocks, Dividend Stocks, Digital Health, Cloud-Connected Devices, SaaS Healthcare, COPD Treatment, Home Medical Equipment, Philips Recall, Emerging Markets Healthcare